Option chain shows key data for Nexalin Technology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nexalin Technology.

Nexalin Technology (NASDAQ:NXL) Stock, Option Chain

Nexalin Technology

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Wall Street

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CERO

EFSH

FOXO

HOVR

MNDY

RAPT

Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results

Biotech

Health Care

Exclusives

General

NXLIW

Nexalin says the study published in the Journal of Alzheimer&#39;s Disease shows DIFS may enhance cognition in mild Alzheimer&#39;s patients.

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer&#39;s Patients (UPDATED)

Market-Moving Exclusives

Nexalin Technology&#39;s clinical trial results highlight notable cognitive improvements in Alzheimer&#39;s patients using Deep Intracranial Frequency Stimulation technology. The study showed significant memory and cognition gains, increased hippocampal activity, and minimal side effects.

EXCLUSIVE: Nano-Cap Nexalin&#39;s Drug-Free Alternative For Alzheimer&#39;s Shows Improved Memory, Cognitive Function In Small Study

Nexalin Technology Inc

NEXLIVING CMNTYS INC by NEXLIVING CMNTYS INC.

Nuix Ltd

Press Releases

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity  in Clinical Trials for mTBI and PTSD Treatment

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

HeartBeam

Biomerica

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Nexalin Technology

Nexalin Technology (NXL) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell